Type to search

Receives $15.00 Consensus Price Target from Brokerages


Receives $15.00 Consensus Price Target from Brokerages


Molecular Templates log Molecular Templates Inc (NASDAQ: MTEM) has obtained a mean rating of “Hold” from the 11 scores companies presently protecting the inventory, MarketBeat Rating reviews. In addition, three equities research analysts have rated the inventory with a promote score, and 7 have assigned a buy score to the company. The average twelve-month target charge amongst brokerages that have issued a document at the inventory inside the closing yr is $15.00.

Several studies analysts have lately weighed in on MTEM shares. Zacks Investment Research downgraded Molecular Templates from a “hold” score to a “sell” score in studies. Be aware on Friday, August 16th. UBS Group commenced insurance on Molecular Templates in a research observe on Monday, April 29th. They issued a “purchase” rating and a $12.00 goal price for the agency. Cowen restated a “purchase” rating on stocks of Molecular Templates in a studies word on Tuesday, August 13th. BidaskClub downgraded Molecular Templates from a “maintain” rating to a “sell” score in a research observe on Friday, July 26th. Finally, TheStreet downgraded Molecular Templates from a “c-” score to a “d” rating in a research word on Monday, August 5th.

MTEM inventory opened at $5.00 on Thursday. The organization has a debt-to-fairness ratio of 0.15, a short ratio of 3.11, and a contemporary ratio of 3.11. The organization has a marketplace capitalization of $193.55 million, a charge-to-income ratio of -4.Ninety and a beta of 2.77. Molecular Templates has a 52 week low of $3.19 and a 52 week high of $8.77. The stock has a 50 day shifting common of $6.41 and a two hundred-day moving average of $6.48.

Price Target

Molecular Templates (NASDAQ: MTEM) ultimately published its quarterly profits consequences on Monday, August twelfth. The biotechnology organization mentioned ($0.25) income in keeping with proportion for the area, lacking the consensus estimate of ($0.23) using ($0.02). The firm had sales of $5.45 million for the sector compared to the consensus estimate of $6.00 million. Molecular Templates negatively affected the fairness of 27.72% and a terrible internet margin of 113.85%. Equities analysts expect that Molecular Templates will put up -0.92 EPS for the contemporary yr.

A quantity of hedge price range and other institutional buyers have changed their commercial enterprise holdings these days. BlackRock Inc. Boosted its function in stocks of Molecular Templates by 51.1% at some stage in the second zone. BlackRock Inc. Now owns 1,080,557 stocks of the biotechnology organization’s stock worth $9,023,000 after acquiring an additional 365,350 stocks during the last quarter. Point72 Asset Management L.P. bought a brand new stake in stocks of Molecular Templates during the 2nd region worth approximately $1,682,000. Vanguard Group Inc. boosted its position in shares of Molecular Templates via 10.4% at some stage in the 2d sector. Vanguard Group Inc.

Now owns 740,883 shares of the biotechnology organization’s stock valued at $6,187,000 after obtaining an extra 69,704 stocks over the last zone. In addition, Renaissance Technologies LLC boosted its position in shares of Molecular Templates by using 453.7% at some point in the second quarter. Renaissance Technologies LLC now owns 81,400 stocks of the biotechnology company’s stock valued at $680,000 after acquiring an additional 66,700 stocks over the last quarter. Finally, Wells Fargo & Company MN boosted its role in stocks of Molecular Templates by using 557.7% in the second region. Wells Fargo & Company MN now owns 78,381 stocks of the biotechnology corporation’s stock valued at $654,000 after obtaining a further 66,464 shares over the past quarter. Institutional buyers and hedge funds personal 38.29% of the enterprise’s inventory.

About Molecular Templates

Molecular Templates, Inc, a scientific stage oncology organization, focuses on discovering and developing biological therapeutics for the remedy of cancer and different illnesses. The corporation primarily develops a pipeline of engineered toxin bodies. Its lead drug candidate is MT-3724 in Phase II clinical trial to treat relapsed/refractory diffuse big B-cellular lymphoma; and a Phase II medical trial for treating non-Hodgkin’s lymphoma.

Calvin M. Barker

Typical tv scholar. Problem solver. Writer. Extreme bacon fan. Twitter maven. Music evangelist. Spent a year consulting about salsa in Fort Lauderdale, FL. Spoke at an international conference about lecturing about junk food in New York, NY. Earned praise for promoting robotic shrimp in Phoenix, AZ. Spent 2002-2007 working on catfish in Naples, FL. Spent several months developing yogurt in Orlando, FL. Spent high school summers managing dandruff in Africa.